Long-Term Effects of Alemtuzumab on Regulatory and Memory T-Cell Subsets in Kidney Transplantation

C. Macedo,J. Walters,E. A. Orkis,K. Isse,B. Elinoff,S. Fedorek,J. McMichael,G. Chalasani,P. Randhawa,A. Demetris,A. Zeevi,H. Tan,R. Shapiro,D. Landsittel,Fadi G Lakkis

DOI: https://doi.org/10.1097/TP.0b013e318247a717

2012-04-27

Transplantation

Abstract:Background. Induction with lymphocyte-depleting antibodies is routinely used to prevent rejection but often skews T cells toward memory. It is not fully understood which memory and regulatory T-cell subsets are most affected and how they relate to clinical outcomes. Methods. We analyzed T cells from 57 living-donor renal transplant recipients (12 reactive and 45 quiescent) 2.8±1.4 years after alemtuzumab induction. Thirty-four healthy subjects and nine patients with acute cellular rejection (ACR) were also studied. Results. We found that alemtuzumab caused protracted CD4 more than CD8 T-lymphocyte deficiency, increased proportion of CD4+ memory T cells, and decreased proportion of CD4+ regulatory T cells. Reactive patients exhibited higher proportions of CD4+ effector memory T cells (TEM) and CD8+ terminally differentiated TEM (TEMRA), with greater CD4+ TEM and CD8+ TEMRA to regulatory T cell ratios, than quiescent patients or healthy controls. Patients with ongoing ACR had profound reduction in circulating CD8+ TEMRA. Mixed lymphocyte assays showed significantly lower T-cell proliferation to donor than third-party antigens in the quiescent group, while reactive and ACR patients exhibited increased effector molecules in CD8+ T cells. Conclusions. Our findings provide evidence that T-cell skewing toward TEM may be associated with antigraft reactivity long after lymphodepletion. Further testing of TEM and TEMRA subsets as rejection predictors is warranted.